Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
1.3
Journals
Transplantology
Special Issues
2021 Profile Papers by Transplantology’s Editorial Board Members
share announcement

2021 Profile Papers by Transplantology’s Editorial Board Members

A special issue of Transplantology (ISSN 2673-3943).

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 20224

Special Issue Editors

Prof. Dr. Giuseppe Lucarelli

E-Mail Website
Guest Editor
Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation—Urology, University of Bari “Aldo Moro”, 70124 Bari, Italy
Interests: kidney cancer; prostate cancer; kidney transplantation; metabolomics
Special Issues, Collections and Topics in MDPI journals
Dr. Avnesh S. Thakor

E-Mail Website
Guest Editor
Interventional Radiology, Lucile Packard Children’s Hospital & Stanford University Medical Center, Palo Alto, CA 94304, USA
Interests: islet transplantation; pancreatic regeneration; mesenchymal stem cells; kidney regeneration; exosomes
Dr. Brian C. Keller

E-Mail Website
Guest Editor
Lung Transplant Program, Massachusetts General Hospital, 55 Fruit Street, Cox 201, Boston, MA 02114, USA
Interests: lung transplantation; viral infections; multiomics analyses of the airway virome and microbiome; allograft dysfunction and emerging therapies
Dr. Taisto Sarkola

E-Mail Website
Guest Editor
Division of Cardiology, Children's Hospital, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland
Interests: transplantation; congenital heart disease; fetal cardiology; cardiovascular disease risk

Special Issue Information

Dear Colleagues,

This Special Issue is dedicated to recent advances in all areas of transplantation and comprises a selection of exclusive papers of the Editorial Board Members (EBMs) of Transplantology. Both original research articles and comprehensive review papers are welcome. The papers will be published *free of charge*, with full open access after peer review.

Prof. Dr. Giuseppe Lucarelli
Dr. Avnesh S. Thakor
Dr. Brian C. Keller
Dr. Taisto Sarkola
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Transplantology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 938 KiB  
Article
Review of Outcomes after Diagnosis of Malignancy in Kidney Transplant Patients: UNOS Database
by Het Patel, Nikhil Agrawal, Voravech Nissaisorakarn, Ridhi Gupta and Francesca Cardarelli
Transplantology 2021, 2(3), 253-263; https://doi.org/10.3390/transplantology2030024 - 24 Jun 2021
Viewed by 3065
Abstract
Malignancy is the third major cause of death among transplant recipients. Patient and kidney transplant outcomes after the diagnosis of malignancy are not well described. We reviewed incidences and outcomes of colorectal, lung, PTLD, and renal malignancy after transplant among patients who received [...] Read more.
Malignancy is the third major cause of death among transplant recipients. Patient and kidney transplant outcomes after the diagnosis of malignancy are not well described. We reviewed incidences and outcomes of colorectal, lung, PTLD, and renal malignancy after transplant among patients who received a transplant from January 2000 to December 2018 using the UNOS/OPTN database. Incidence of each malignancy was measured at 5 years and 10 years of transplant. The Kaplan–Meier curve was used for time-to-event analysis (graft and patient outcomes). Additionally, we sought to identify the causes of graft failure among these recipients. We found that 12,764 (5.5%) patients suffered malignancy, excluding squamous and basal cell skin carcinoma after transplant. During the first 5 years of transplant, incidence of colorectal, lung, PTLD, and renal malignancies was 2.99, 9.21, 15.61, and 8.55 per 10,000 person-years, respectively. Rates of graft failure were 10.3%, 7.6%, 19.9%, and 18.8%, respectively, among these patients at 5 years. Mortality rate was highest among patients who suffered lung malignancy (84%), followed by colorectal (61.5%), PTLD (49.1%), and renal (35.5%) at 5 years after diagnosis of malignancy. In conclusion, kidney transplant recipients diagnosed with lung malignancy have the lowest graft survival, compared to PTLD, colorectal, and renal malignancy. PTLD has the highest incidence rate in the first 5 years of transplant. Full article
(This article belongs to the Special Issue 2021 Profile Papers by Transplantology’s Editorial Board Members)
►▼ Show Figures

Figure 1

15 pages, 2187 KiB  
Article
Urological Complications in Kidney Transplant Recipients: Analysis of the Risk Factors and Impact on Transplant Outcomes in the Era of “Extended Criteria Donors”
by Roberta Angelico, Marco Pellicciaro, Francesca Venza, Tommaso Maria Manzia, Roberto Cacciola, Alessandro Anselmo, Luca Toti, Andrea Monaco, Giuseppe Iaria and Giuseppe Tisone
Transplantology 2021, 2(1), 22-36; https://doi.org/10.3390/transplantology2010003 - 20 Jan 2021
Cited by 3 | Viewed by 3924
Abstract
Urological complications (UC) following kidney transplantation (KT) are associated with increased morbidity. The aim of this study is to evaluate the risk factors for UC in the era of “extended criteria donors” (ECD) and their impact on patient and graft survivals. A retrospective [...] Read more.
Urological complications (UC) following kidney transplantation (KT) are associated with increased morbidity. The aim of this study is to evaluate the risk factors for UC in the era of “extended criteria donors” (ECD) and their impact on patient and graft survivals. A retrospective monocentric study of all patients undergoing KT from 2010 to 2019 with a follow-up ≥30 days was performed. Out of 459 patients (males: 296 (64.5%); age: 57 (19–77) years) enrolled, 228 (49.7%) received ECD organs, moreover, 166 (67.2%) grafts had a cold ischemia time ≥10 h. UCs were reported in 32 (7%) patients. In 21 (65.6%) cases UC occurred within 3 months post-KT and 24 (5.2%) were associated with early urinary tract infection (UTI). The overall 5 year patient and graft survival rates were 96.5% and 90.6%, respectively. UC decreased graft survival (UC-group: 75.0% vs. noUC-group: 91.8%, p < 0.001), especially if associated with early UTI (UC-group: 71.4% vs. noUC-group: 77.8%, p < 0.001). At multivariate analysis, early UTI after KT (OR: 9.975, 95%-IC: 2.934–33.909, p < 0.001) and delayed graft function (DGF) (OR: 3.844, 95%-IC: 1.328–11.131, p: 0.013) were significant risk factors for UC, while ECD graft did not increase the risk of post-transplant UC. ECD grafts are not associated with UC. DGF and early UTI post-KT increase the risks of UC and reduce graft survival in the long-term. Therefore, aggressive management of early post-transplant UTI and strategies to reduce DGF incidence, such as machine preservation, are essential to prevent UC after KT. Full article
(This article belongs to the Special Issue 2021 Profile Papers by Transplantology’s Editorial Board Members)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 923 KiB  
Review
Novel Insights into the Molecular Mechanisms of Ischemia/Reperfusion Injury in Kidney Transplantation
by Davide Loizzo, Nicola Antonio di Meo, Mattia Rocco Peluso, Monica Rutigliano, Matteo Matera, Carlos Miacola, Gaetano Palella, Michele Tedeschi, Marco Spilotros, Matteo Ferro, Octavian Sabin Tătaru, Mihai Dorin Vartolomei, Leonardo Vincenti, Pasquale Ditonno, Michele Battaglia and Giuseppe Lucarelli
Transplantology 2021, 2(2), 191-207; https://doi.org/10.3390/transplantology2020018 - 28 May 2021
Cited by 5 | Viewed by 4115
Abstract
Ischemia reperfusion injury (IRI) is one of the most important mechanisms involved in delayed or reduced graft function after kidney transplantation. It is a complex pathophysiological process, followed by a pro-inflammatory response that enhances the immunogenicity of the graft and the risk of [...] Read more.
Ischemia reperfusion injury (IRI) is one of the most important mechanisms involved in delayed or reduced graft function after kidney transplantation. It is a complex pathophysiological process, followed by a pro-inflammatory response that enhances the immunogenicity of the graft and the risk of acute rejection. Many biologic processes are involved in its development, such as transcriptional reprogramming, the activation of apoptosis and cell death, endothelial dysfunction and the activation of the innate and adaptive immune response. Recent evidence has highlighted the importance of complement activation in IRI cascade, which expresses a pleiotropic action on tubular cells, on vascular cells (pericytes and endothelial cells) and on immune system cells. The effects of IRI in the long term lead to interstitial fibrosis and tubular atrophy, which contribute to chronic graft dysfunction and subsequently graft failure. Furthermore, several metabolic alterations occur upon IRI. Metabolomic analyses of IRI detected a “metabolic profile” of this process, in order to identify novel biomarkers that may potentially be useful for both early diagnosis and monitoring the therapeutic response. The aim of this review is to update the most relevant molecular mechanisms underlying IRI, and also to discuss potential therapeutic targets in future clinical practice. Full article
(This article belongs to the Special Issue 2021 Profile Papers by Transplantology’s Editorial Board Members)
►▼ Show Figures

Figure 1

16 pages, 905 KiB  
Review
White Adipose Tissue as a Site for Islet Transplantation
by Naoaki Sakata, Gumpei Yoshimatsu and Shohta Kodama
Transplantology 2020, 1(2), 55-70; https://doi.org/10.3390/transplantology1020006 - 1 Sep 2020
Cited by 6 | Viewed by 3614
Abstract
Although islet transplantation is recognized as a useful cellular replacement therapy for severe diabetes, surgeons face difficulties in islet engraftment. The transplant site is a pivotal factor that influences the engraftment. Although the liver is the current representative site for clinical islet transplantation, [...] Read more.
Although islet transplantation is recognized as a useful cellular replacement therapy for severe diabetes, surgeons face difficulties in islet engraftment. The transplant site is a pivotal factor that influences the engraftment. Although the liver is the current representative site for clinical islet transplantation, it is not the best site because of limitations in immunity, inflammation, and hypoxia. White adipose tissue, including omentum, is recognized as a useful candidate site for islet transplantation. Its effectiveness has been evaluated in not only various basic and translational studies using small and large animals but also in some recent clinical trials. In this review, we attempt to shed light on the characteristics and usefulness of white adipose tissue as a transplant site for islets. Full article
(This article belongs to the Special Issue 2021 Profile Papers by Transplantology’s Editorial Board Members)
►▼ Show Figures

Graphical abstract

18 pages, 714 KiB  
Review
Non-HLA Abs in Solid Organ Transplantation
by María Gutiérrez-Larrañaga, Marcos López-Hoyos, André Renaldo and David San Segundo
Transplantology 2020, 1(1), 24-41; https://doi.org/10.3390/transplantology1010003 - 15 Jul 2020
Cited by 4 | Viewed by 4549
Abstract
The role of anti-HLA antibodies in solid organ rejection is well established and these antibodies are routinely monitored both in patients in the waiting list and in the post-transplant setting. More recently, the presence of other antibodies directed towards non-HLA antigens, or the [...] Read more.
The role of anti-HLA antibodies in solid organ rejection is well established and these antibodies are routinely monitored both in patients in the waiting list and in the post-transplant setting. More recently, the presence of other antibodies directed towards non-HLA antigens, or the so-called minor histocompatibility antigens, has drawn the attention of the transplant community; however, their possible involvement in the graft outcome remains uncertain. These antibodies have been described to possibly have a role in rejection and allograft failure. This review focuses on the most studied non-HLA antibodies and their association with different clinical outcomes considered in solid organ transplantation with the aim of clarifying their clinical implication and potential relevance for routine testing. Full article
(This article belongs to the Special Issue 2021 Profile Papers by Transplantology’s Editorial Board Members)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop